Key Highlights
- BlossomHill Therapeutics (Nasdaq: BLSM) reported updated Phase 1/2 SOLARA results for oral OMNI-EGFR candidate BH-30643.
- Across 40 subjects with EGFR C797S-positive NSCLC, the therapy produced a 45% objective response rate and 88% disease control rate.
- BH-30643 holds FDA Fast Track Designation and targets a resistance setting with no approved options.
- Shares of BlossomHill Therapeutics (Nasdaq: BLSM) closed up 18% at $26.25.
SOLARA Data Show Meaningful Response Rates
BlossomHill Therapeutics (Nasdaq: BLSM) reported updated results from its Phase 1/2 SOLARA trial evaluating BH-30643, an oral OMNI-EGFR candidate, in patients with EGFR C797S-positive non-small cell lung cancer. Over a median follow-up of 6.9 months across 40 subjects, the therapy delivered a 45% objective response rate and an 88% disease control rate.
Addressing a Resistance Gap
The data come with a favorable tolerability profile and FDA Fast Track designation already in hand. BH-30643 is being developed for patients who have progressed on third-generation EGFR inhibitors and developed C797S resistance mutations, a setting where no approved targeted therapies currently exist. BlossomHill Therapeutics (Nasdaq: BLSM) is advancing the candidate as a potential option for this underserved patient population.
Shares Climb on Data
Shares of BlossomHill Therapeutics (Nasdaq: BLSM) closed up 18% at $26.25 following the update, as investors responded to the response and disease control rates in a resistance setting that currently lacks approved targeted treatments.
What is BH-30643?
An oral OMNI-EGFR candidate being developed by BlossomHill Therapeutics for EGFR C797S-positive non-small cell lung cancer.
What did the SOLARA trial show?
A 45% objective response rate and 88% disease control rate across 40 subjects over a median 6.9-month follow-up.
What regulatory status does BH-30643 have?
FDA Fast Track designation.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...